Analytical Data
-
基因名
ICAM-3/CD50
- Application
-
别名
CDW50; CD50; ICAM-R
-
种属
Human
-
表达系统
E. coli
-
标签
N-His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P32942
-
表达区间
Gln30~His485
-
分子量
40kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
ICAM-3 (Intercellular Adhesion Molecule 3) and CD50 (also known as CD2LG or LFA-3) are critical adhesion molecules involved in the immune response, particularly in the interactions between leukocytes and endothelial cells. These proteins play significant roles in cell signaling and migration, influencing processes such as inflammation and immune regulation. Research has shown that ICAM-3 functions as a ligand for LFA-1, promoting leukocyte adhesion and traversal through endothelium during immune responses. Meanwhile, CD50 interacts with CD2 on T cells, facilitating T cell activation and enhancing immune responses. Given their importance in immune cell interactions, understanding the structure and function of these proteins is essential for developing targeted therapies in various immune-related disorders, including autoimmune diseases and cancer. Recombinant ICAM-3/CD50 proteins are generated to study their biochemical properties, signaling pathways, and potential therapeutic applications. The ability to produce these proteins in a laboratory setting allows researchers to explore their roles in immune modulation and to screen for inhibitors or agonists that could serve as novel treatments. Overall, the study of ICAM-3/CD50 recombinant proteins offers valuable insights into immune dynamics and could lead to advancements in immunotherapy and the treatment of immune-mediated diseases.
